Macik B G
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Semin Thromb Hemost. 1993;19(1):13-24. doi: 10.1055/s-2007-994002.
Treatment of patients with inhibitors to FVIII remains a complex clinical problem. Although characterizing the individual patient may aid in the initial development of a care plan, no treatment is uniformly reliable for all patients. Experts in the field are as likely to disagree as agree when it comes to choosing treatment options; few randomized clinical trials exist on which to base decisions.